EYDENZELT
LaunchBLAINJECTIONINJECTABLE
Approved
Oct 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
4/8 — Partial
EYDENZELT by Celltrion is factor-a (vegf-a) and placental growth factor (plgf) are members of the vegf family of angiogenic factors that can act as mitogenic, chemotactic, and vascular permeability factors for endothelial cells. First approved in 2025.
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EYDENZELT (aflibercept) is a fusion protein VEGF inhibitor administered by intravitreal injection for retinal vascular diseases. It treats neovascular age-related macular degeneration, diabetic macular edema, and polypoidal choroidal vasculopathy by blocking vascular endothelial growth factor signaling. This biosimilar/follow-on biologic from Celltrion enters a crowded ophthalmology market dominated by Regeneron's EYLEA.
Launch
Early-stage launch from a biosimilar innovator (Celltrion) entering a mature, competitive market; expects moderate team expansion during market penetration phase.
Mechanism of Action
factor-A (VEGF-A) and placental growth factor (PlGF) are members of the VEGF family of angiogenic factors that can act as mitogenic, chemotactic, and vascular permeability factors for endothelial cells. VEGF acts via two receptor tyrosine kinases, VEGFR-1 and VEGFR-2, present on the surface of…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Worked on EYDENZELT at Celltrion? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.